MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Antoon, James W ^a   Martin, Elizabeth C ^a   Lai, Rongye ^c   Salvo, Virgilo A ^a   Tang, Yan ^a   Nitzchke, Ashley M ^a   Elliott, Steven ^a   Nam, Seung Yoon ^b   Xiong, Wei ^a   Rhodes, Lyndsay V ^a   Collins Burow, Bridgette ^a   David, Odile ^a   Wang, Guandi ^b   Shan, Bin ^a   Beckman, Barbara S ^a   Nephew, Kenneth P ^c   Burow, Matthew E ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b XAVIER UNIVERSITY OF LOUISIANA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; ER ALPHA GENE; ER BETA GENE; ERK5 GENE; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MEK5 GENE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

EID: 84881250378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069291     Document Type: Article

References (54)

1. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, et al. (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339.
2. Musgrove EA, Sutherland RL, (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643.
3. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, et al. (2009) Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 27: 542-549.
4. Thompson EW, Newgreen DF, Tarin D, (2005) Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65: 5991-5995 discussion 5995.
5. Whyte J, Bergin O, Bianchi A, McNally S, Martin F, (2009) Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res 11: 209.
6. Cavanaugh JE, (2004) Role of extracellular signal regulated kinase 5 in neuronal survival. Eur J Biochem 271: 2056-2059.
7. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, et al. (1998) Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 713-716.
8. Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D, (2007) Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 13: 7029-7036.
9. Brinkman JA, El-Ashry D, (2009) ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia 14: 67-78.
10. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, et al. (2006) Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66: 3903-3911.
11. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, et al. (2001) Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 15: 1344-1359.
12. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC, (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483.
13. Drew BA, Burow ME, Beckman BS, (2012) MEK5/ERK5 pathway: The first fifteen years. Biochim Biophys Acta 1825: 37-48.
14. Yang Q, Deng X, Lu B, Cameron M, Fearns C, et al. (2010) Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18: 258-267.
15. Hsieh FC, Cheng G, Lin J, (2005) Evaluation of potential Stat3-regulated genes in human breast cancer. Biochemical and biophysical research communications 335: 292.
16. Montero JC, Ocana A, Abad M, Ortiz-Ruiz MJ, Pandiella A, et al. (2009) Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 4: e5565.
17. Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, et al. (2002) Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 132: 293-301.
18. Hsieh F, Cheng G, Lin J, (2005) Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 335: 292-299.
19. Buschbeck M, Eickhoff J, Sommer MN, Ullrich A, (2002) Phosphotyrosine-specific phosphatase PTP-SL regulates the ERK5 signaling pathway. J Biol Chem 277: 29503-29509.
20. Cavanaugh JE, Ham J, Hetman M, Poser S, Yan C, et al. (2001) Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci 21: 434-443.
21. Cavanaugh JE, Jaumotte JD, Lakoski JM, Zigmond MJ, (2006) Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress. J Neurosci Res 84: 1367-1375.
22. Wang X, Tournier C, (2006) Regulation of cellular functions by the ERK5 signalling pathway. Cellular Signalling 18: 753-760.
23. Kamakura S, Moriguchi T, Nishida E, (1999) Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. Journal of Biological Chemistry 274: 26563.
24. Buschbeck M, Ullrich A, (2005) The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. J Biol Chem 280: 2659-2667.
25. Yan C, Luo H, Lee JD, Abe J, Berk BC, (2001) Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains. J Biol Chem 276: 10870-10878.
26. Pearson G, English JM, White MA, Cobb MH, (2001) ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem 276: 7927-7931.
27. Weldon CB, McKee A, Collins-Burow BM, Melnik LI, Scandurro AB, et al. (2005) PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling. Int J Oncol 26: 763-768.
28. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, et al. (2003) MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 22: 1381-1389.
29. Huang A, Pettigrew NM, Watson PH, (1996) Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol 180: 223-227.
30. Vereide AB, Kaino T, Sager G, Arnes M, Orbo A, (2006) Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 101: 214-223.
31. Duong BN, Elliott S, Frigo DE, Melnik LI, Vanhoy L, et al. (2006) AKT regulation of estrogen receptor beta transcriptional activity in breast cancer. Cancer Res 66: 8373-8381.
32. Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, et al. (2010) Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 151: 5124-5135.
33. Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, et al. (1998) Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 58: 4940-4946.
34. Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, et al. (2008) Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res 10: R105.
35. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, et al. (2011) Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 71: 603-613.
36. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, et al. (2006) Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66: 11954-11966.
37. Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, et al. (2009) Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem 52: 5748-5752.
38. Dimple C, Nair SS, Rajhans R, Pitcheswara PR, Liu J, et al. (2008) Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res 68: 4902-4909.
39. Payton-Stewart F, Schoene NW, Kim YS, Burow ME, Cleveland TE, et al. (2009) Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP. Mol Carcinog 48: 862-871.
40. Rhodes LV, Antoon JW, Muir SE, Elliott S, Beckman BS, et al. (2010) Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer 9: 295.
41. Xin F, Li M, Balch C, Thomson M, Fan M, et al. (2009) Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 25: 430-434.
42. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
43. Rubio MF, Werbajh S, Cafferata EG, Quaglino A, Colo GP, et al. (2006) TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene 25: 1367-1377.
44. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB, (2005) Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 18: 71-82.
45. McPherson LA, Baichwal VR, Weigel RJ, (1997) Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci U S A 94: 4342-4347.
46. Zhang X, Leung YK, Ho SM, (2007) AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells. Oncogene 26: 7346-7354.
47. Zhao C, Yasui K, Lee CJ, Kurioka H, Hosokawa Y, et al. (2003) Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 98: 18-23.
48. Kamakura S, Moriguchi T, Nishida E, (1999) Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 274: 26563-26571.
49. Woodfield GW, Horan AD, Chen Y, Weigel RJ, (2007) TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res 67: 8439-8443.
50. Gee JM, Eloranta JJ, Ibbitt JC, Robertson JF, Ellis IO, et al. (2009) Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol 217: 32-41.
51. Cameron SJ, Abe J, Malik S, Che W, Yang J, (2004) Differential role of MEK5alpha and MEK5beta in BMK1/ERK5 activation. J Biol Chem 279: 1506-1512.
52. Sosic D, Richardson JA, Yu K, Ornitz DM, Olson EN, (2003) Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell 112: 169-180.
53. Thiery JP, Morgan M, (2004) Breast cancer progression with a Twist. Nat Med 10: 777-778.
54. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, et al. (2007) NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26: 711-724.